MicuRx Inc. is a clinical-stage biopharmaceutical company advancing a diversified pipeline addressing major unmet needs in infectious, respiratory, renal, and oncology diseases.

We are seeking strategic investors and partners to accelerate the development of:

• MRX-5 – A Phase 2–ready small molecule targeting rare chronic pulmonary NTM disease. First-in-class and first-in-disease candidate for NTM M. abscessus, offering a novel therapeutic approach in a market with no approved treatments.

• Contezolid (oral and IV) – Phase 3 program for diabetic foot infection, with demonstrated efficacy and a superior safety profile over existing agents.

• Preclinical ADC pipeline
• RMT-001: Bispecific ADC targeting solid tumors.
• RMT-002: Novel target with proprietary STOPIN payload, focused on pancreatic, biliary tract, and liver cancers.

MicuRx combines proven clinical execution with innovation across multiple therapeutic areas—positioning the company for significant near- and long-term value creation.